Daily Pharma Scoop 2017-09-25: Gilead at mid-80s , Keytruda new label, Ascendis positive trial
- A Gilead article is discussed - should it be bought now?
- Keytruda gets a new label.
- Ascendis is up on Versartis phase 3 failure in pediatric growth hormone deficiency.
Analysis of top Seeking Alpha coverage
Why We Bought Gilead This Week by RobinhoodStrategy - This is not an Editor’s Pick article, however, this weekend there are no proper Editor’s Picks in healthcare so we will go with this one mainly because I am interested to know why someone would buy Gilead (GILD) now and not when it was below $70. 🙂
The full unabridged post was first published, and can be accessed, on SeekingAlpha Marketplace.